{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-029629","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.199651+00:00","generated_at":"2026-05-23T18:57:38.807117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M","bullets":["Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.","Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.","Cash and short-term investments at March 31, 2025: approx. $77.5M.","Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.","Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-029629","json":"https://secwatch.observer/filing/0001213900-25-029629.json","markdown":"https://secwatch.observer/filing/0001213900-25-029629.md","text":"https://secwatch.observer/filing/0001213900-25-029629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/0001213900-25-029629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:57:38.807117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}